The University of Chicago Header Logo

Connection

Mark J. Ratain to Glucuronosyltransferase

Back to Details
This is a "connection" page, showing publications Mark J. Ratain has written about Glucuronosyltransferase.
Mark J. Ratain
Connection Strength
6.463
Glucuronosyltransferase
  1. In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7. Xenobiotica. 2015; 45(11):990-8.
    View in: PubMed
    Score: 0.458
  2. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014 Aug 01; 32(22):2328-34.
    View in: PubMed
    Score: 0.429
  3. Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol. 2010 Apr; 6(4):563-85.
    View in: PubMed
    Score: 0.320
  4. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? Pharmacotherapy. 2008 Jun; 28(6):755-68.
    View in: PubMed
    Score: 0.282
  5. Pharmacogenetic pathway analysis of irinotecan. Clin Pharmacol Ther. 2008 Sep; 84(3):393-402.
    View in: PubMed
    Score: 0.279
  6. Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms. PLoS One. 2007 Apr 25; 2(4):e396.
    View in: PubMed
    Score: 0.261
  7. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics. 2006 Dec; 7(8):1211-21.
    View in: PubMed
    Score: 0.254
  8. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci. 2006 Aug; 27(8):432-7.
    View in: PubMed
    Score: 0.247
  9. Irinogenetics: what is the right star? J Clin Oncol. 2006 May 20; 24(15):2221-4.
    View in: PubMed
    Score: 0.243
  10. From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. Clin Cancer Res. 2006 Mar 15; 12(6):1658-60.
    View in: PubMed
    Score: 0.242
  11. Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clin Cancer Res. 2005 Sep 15; 11(18):6699-704.
    View in: PubMed
    Score: 0.233
  12. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics. 2005 May; 15(5):295-301.
    View in: PubMed
    Score: 0.227
  13. Linkage disequilibrium across the UGT1A locus should not be ignored in association studies of cancer susceptibility. Clin Cancer Res. 2005 Feb 01; 11(3):1348-9; author reply 1349.
    View in: PubMed
    Score: 0.224
  14. "Irinogenetics" and UGT1A: from genotypes to haplotypes. Clin Pharmacol Ther. 2004 Jun; 75(6):495-500.
    View in: PubMed
    Score: 0.213
  15. UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics. 2003 Aug; 13(8):517-23.
    View in: PubMed
    Score: 0.201
  16. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Oncology (Williston Park). 2003 May; 17(5 Suppl 5):52-5.
    View in: PubMed
    Score: 0.198
  17. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998 Feb 15; 101(4):847-54.
    View in: PubMed
    Score: 0.138
  18. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther. 2016 04; 99(4):363-9.
    View in: PubMed
    Score: 0.118
  19. Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10. Drug Metab Dispos. 2015 Jul; 43(7):928-35.
    View in: PubMed
    Score: 0.113
  20. UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):94-104.
    View in: PubMed
    Score: 0.109
  21. Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver. Hum Mol Genet. 2014 Oct 15; 23(20):5558-69.
    View in: PubMed
    Score: 0.107
  22. Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One. 2013; 8(1):e54522.
    View in: PubMed
    Score: 0.097
  23. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst. 2012 Aug 22; 104(16):1264; author reply 1266-8.
    View in: PubMed
    Score: 0.094
  24. Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. Br J Clin Pharmacol. 2011 Jun; 71(6):917-20.
    View in: PubMed
    Score: 0.087
  25. A pharmacogenetic study of vorinostat glucuronidation. Pharmacogenet Genomics. 2010 Oct; 20(10):638-41.
    View in: PubMed
    Score: 0.083
  26. The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation. Eur J Cancer. 2010 Jul; 46(11):2097-103.
    View in: PubMed
    Score: 0.081
  27. Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos. 2010 Jan; 38(1):32-9.
    View in: PubMed
    Score: 0.079
  28. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet Genomics. 2008 Aug; 18(8):683-97.
    View in: PubMed
    Score: 0.071
  29. Lack of association between common polymorphisms in UGT1A9 and gene expression and activity. Drug Metab Dispos. 2007 Dec; 35(12):2149-53.
    View in: PubMed
    Score: 0.067
  30. UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Pharmacogenet Genomics. 2007 Aug; 17(8):619-27.
    View in: PubMed
    Score: 0.066
  31. Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver. Pharmacogenomics J. 2008 Apr; 8(2):152-61.
    View in: PubMed
    Score: 0.065
  32. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol. 2007 Jan; 47(1):78-86.
    View in: PubMed
    Score: 0.064
  33. Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes. Pharmacogenet Genomics. 2006 Feb; 16(2):79-86.
    View in: PubMed
    Score: 0.060
  34. Global gene expression as a function of germline genetic variation. Hum Mol Genet. 2005 Jun 15; 14(12):1621-9.
    View in: PubMed
    Score: 0.057
  35. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 Apr 15; 22(8):1382-8.
    View in: PubMed
    Score: 0.052
  36. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther. 2003 Jun; 73(6):566-74.
    View in: PubMed
    Score: 0.050
  37. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics. 2002 Dec; 12(9):725-33.
    View in: PubMed
    Score: 0.048
  38. In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharm Res. 2002 May; 19(5):588-94.
    View in: PubMed
    Score: 0.046
  39. Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"? J Clin Oncol. 2002 Jan 01; 20(1):7-8.
    View in: PubMed
    Score: 0.045
  40. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2(1):43-7.
    View in: PubMed
    Score: 0.045
  41. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos. 2001 May; 29(5):686-92.
    View in: PubMed
    Score: 0.043
  42. Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer. J Clin Oncol. 2001 Apr 01; 19(7):2084-90.
    View in: PubMed
    Score: 0.043
  43. Pharmacogenetics: a tool for individualizing antineoplastic therapy. Clin Pharmacokinet. 2000 Nov; 39(5):315-25.
    View in: PubMed
    Score: 0.042
  44. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther. 1999 May; 65(5):576-82.
    View in: PubMed
    Score: 0.037
  45. Pharmacogenetics in cancer etiology and chemotherapy. Clin Cancer Res. 1997 Jul; 3(7):1025-30.
    View in: PubMed
    Score: 0.033
  46. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol. 1997; 39(5):440-4.
    View in: PubMed
    Score: 0.032
  47. Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics. 2013 Jul; 23(7):374-81.
    View in: PubMed
    Score: 0.025
  48. In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec; 70(6):854-69.
    View in: PubMed
    Score: 0.021
  49. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009 Jun 01; 27(16):2604-14.
    View in: PubMed
    Score: 0.019
  50. Effects of green tea compounds on irinotecan metabolism. Drug Metab Dispos. 2007 Feb; 35(2):228-33.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.